JP6312332B2 - 糖尿病バイオマーカ - Google Patents

糖尿病バイオマーカ Download PDF

Info

Publication number
JP6312332B2
JP6312332B2 JP2015514216A JP2015514216A JP6312332B2 JP 6312332 B2 JP6312332 B2 JP 6312332B2 JP 2015514216 A JP2015514216 A JP 2015514216A JP 2015514216 A JP2015514216 A JP 2015514216A JP 6312332 B2 JP6312332 B2 JP 6312332B2
Authority
JP
Japan
Prior art keywords
cell
central memory
therapy
level
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015514216A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015520378A5 (enExample
JP2015520378A (ja
Inventor
オルバン、ティハメル
Original Assignee
ディーエムノーモア リミテッド
ディーエムノーモア リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ディーエムノーモア リミテッド, ディーエムノーモア リミテッド filed Critical ディーエムノーモア リミテッド
Publication of JP2015520378A publication Critical patent/JP2015520378A/ja
Publication of JP2015520378A5 publication Critical patent/JP2015520378A5/ja
Application granted granted Critical
Publication of JP6312332B2 publication Critical patent/JP6312332B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Ecology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2015514216A 2012-05-24 2013-05-24 糖尿病バイオマーカ Active JP6312332B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261651144P 2012-05-24 2012-05-24
US61/651,144 2012-05-24
PCT/US2013/042627 WO2013177505A1 (en) 2012-05-24 2013-05-24 Diabetes biomarkers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018027381A Division JP6761827B2 (ja) 2012-05-24 2018-02-19 糖尿病バイオマーカ

Publications (3)

Publication Number Publication Date
JP2015520378A JP2015520378A (ja) 2015-07-16
JP2015520378A5 JP2015520378A5 (enExample) 2016-11-24
JP6312332B2 true JP6312332B2 (ja) 2018-04-18

Family

ID=49621783

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2015514216A Active JP6312332B2 (ja) 2012-05-24 2013-05-24 糖尿病バイオマーカ
JP2018027381A Expired - Fee Related JP6761827B2 (ja) 2012-05-24 2018-02-19 糖尿病バイオマーカ
JP2020150183A Pending JP2021001899A (ja) 2012-05-24 2020-09-07 糖尿病バイオマーカ
JP2022175993A Pending JP2023011814A (ja) 2012-05-24 2022-11-02 糖尿病バイオマーカ
JP2024120652A Pending JP2024150702A (ja) 2012-05-24 2024-07-25 糖尿病バイオマーカ

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2018027381A Expired - Fee Related JP6761827B2 (ja) 2012-05-24 2018-02-19 糖尿病バイオマーカ
JP2020150183A Pending JP2021001899A (ja) 2012-05-24 2020-09-07 糖尿病バイオマーカ
JP2022175993A Pending JP2023011814A (ja) 2012-05-24 2022-11-02 糖尿病バイオマーカ
JP2024120652A Pending JP2024150702A (ja) 2012-05-24 2024-07-25 糖尿病バイオマーカ

Country Status (13)

Country Link
US (5) US20130316375A1 (enExample)
EP (2) EP2856149B1 (enExample)
JP (5) JP6312332B2 (enExample)
KR (1) KR102172285B1 (enExample)
CN (1) CN104520707B (enExample)
AU (4) AU2013266145A1 (enExample)
CA (1) CA2874507A1 (enExample)
DK (1) DK2856149T3 (enExample)
ES (1) ES2810227T3 (enExample)
IN (1) IN2014DN10259A (enExample)
MX (1) MX357169B (enExample)
WO (1) WO2013177505A1 (enExample)
ZA (1) ZA201409006B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018116061A (ja) * 2012-05-24 2018-07-26 ディーエムノーモア リミテッド 糖尿病バイオマーカ

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8735359B2 (en) 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
AU2013284460A1 (en) 2012-06-27 2015-01-29 Dmnomore CTLA4 fusion proteins for the treatment of diabetes
GB2523399B (en) 2014-02-25 2019-03-13 Orban Tihamer A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence
CN107003315B (zh) * 2014-12-25 2018-09-25 株式会社日立制作所 胰岛素分泌能力分析装置、具备该装置的胰岛素分泌能力分析系统以及胰岛素分泌能力分析方法
CN105567851A (zh) * 2016-02-29 2016-05-11 北京泱深生物信息技术有限公司 一种与糖尿病相关的分子标志物
EP3433612B1 (en) * 2016-03-22 2024-10-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits of assessing status, risk or prognosis of type 1 diabetes
JP7852926B2 (ja) 2020-06-26 2026-04-28 ファイム ファーマ リミテッド 乾癬及び他の自己免疫疾患抗原免疫モジュレータ（ａｉｍ）治療プラットフォーム
WO2022264088A1 (en) 2021-06-17 2022-12-22 Phaim Pharma Ltd. Individualized cell therapy using patient-derived antigen-specific regulatory t cells

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090246212A1 (en) * 2005-09-30 2009-10-01 Kyoto University Development of method for screening for drug capable of improving production of regulatory t cells and method for producing regulatory t cells using immunosuppressive macrolide antibiotic
WO2009120341A2 (en) * 2008-03-24 2009-10-01 University Of South Florida Biomarkers for predicting response to immunosuppressive therapy
US20100080784A1 (en) * 2008-09-12 2010-04-01 Torrey Pines Institute For Molecular Studies Methods for treating cachexia and lymphopenia
US20130316375A1 (en) * 2012-05-24 2013-11-28 Orban Biotech Llc Diabetes biomarkers
JP7618502B2 (ja) * 2021-05-14 2025-01-21 東京計器株式会社 船舶用自動操舵装置

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018116061A (ja) * 2012-05-24 2018-07-26 ディーエムノーモア リミテッド 糖尿病バイオマーカ

Also Published As

Publication number Publication date
EP3767295A1 (en) 2021-01-20
ZA201409006B (en) 2016-07-27
JP2023011814A (ja) 2023-01-24
AU2013266145A1 (en) 2015-01-15
US20190137483A1 (en) 2019-05-09
AU2023222980A1 (en) 2023-09-21
DK2856149T3 (da) 2020-08-17
KR102172285B1 (ko) 2020-11-02
US20250237643A1 (en) 2025-07-24
JP2018116061A (ja) 2018-07-26
JP2021001899A (ja) 2021-01-07
CN104520707B (zh) 2018-03-27
AU2019200824A1 (en) 2019-04-04
US20230333094A1 (en) 2023-10-19
EP2856149A1 (en) 2015-04-08
AU2019200824B2 (en) 2021-06-24
CA2874507A1 (en) 2013-11-28
IN2014DN10259A (enExample) 2015-08-07
ES2810227T3 (es) 2021-03-08
JP2024150702A (ja) 2024-10-23
US20160299128A1 (en) 2016-10-13
MX2014014348A (es) 2015-06-05
CN104520707A (zh) 2015-04-15
US20130316375A1 (en) 2013-11-28
AU2021202609A1 (en) 2021-05-27
JP2015520378A (ja) 2015-07-16
EP2856149A4 (en) 2016-06-01
JP6761827B2 (ja) 2020-09-30
EP2856149B1 (en) 2020-07-08
WO2013177505A1 (en) 2013-11-28
KR20150022878A (ko) 2015-03-04
MX357169B (es) 2018-06-28

Similar Documents

Publication Publication Date Title
JP6761827B2 (ja) 糖尿病バイオマーカ
Couper et al. ISPAD Clinical Practice Consensus Guidelines 2018: Stages of type 1 diabetes in children and adolescents
Aamodt et al. The pathophysiology, presentation and classification of Type 1 diabetes
Iwama et al. Management, biomarkers and prognosis in people developing endocrinopathies associated with immune checkpoint inhibitors
US9726659B2 (en) CMPF as a biomarker for diabetes and associated methods
US20240409633A1 (en) Methods and Compositions for Preventing Type 1 Diabetes
Mallone et al. Biomarkers for immune intervention trials in type 1 diabetes
US20200126671A1 (en) Method for determining the risk to develop type 1 diabetes
Killestein et al. Antibody‐mediated suppression of Vβ5. 2/5.3+ T cells in multiple sclerosis: Results from an MRI‐monitored phase II clinical trial
JP2024535635A (ja) １型糖尿病の処置を予後予測するための方法
Tizazu et al. Low rate of glutamic acid decarboxylase 65 (GAD-65) antibodies in chronic epilepsy
EP3247384B1 (en) In vitro method of diagnosis of type 1 diabetes with insulin mimotopes
US20230034053A1 (en) Metabolic rescue of retinal degeneration
Grönholm et al. Novel diagnostic and therapeutic approaches for autoimmune diabetes—a prime time to treat insulitis as a disease
Roy et al. Synthetic Immunological Niche Reveals Early Immune Dysregulation and Stratifies Therapeutic Response in Type 1 Diabetes
Welsch Characterization and identification of atypical diabetes in pediatric patients
US20100143919A1 (en) In vitro assay for early diagnosis of diabetes mellitus type 1
WO2025174781A1 (en) Use of cardiac autoantibodies as a method to identify individuals at increased risk of developing cardiovascular events
Ghosh Yearbook of Diabetes 2017
Gutlić Latent autoimmune diabetes in adults (LADA)
Keymeulen et al. Predictors of progression to Type 1 diabetes: preparing
Bosch et al. MINUTES OF THE 48th GENERAL ASSEMBLY OF THE EUROPE-AN ASSOCIATION FOR THE STUDY OF DIABETES

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20160419

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160419

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160524

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160524

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170404

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170704

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171219

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180118

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180219

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180319

R150 Certificate of patent or registration of utility model

Ref document number: 6312332

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250